# US 2021/0275442 A1 · Topical skin formulations and wound care products with integrated cbd delivery mechanisms for skin rejuvenation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275442 A1
- Document ID: US20210275442A1
- Status: Published application
- Kind: A1
- Application number: 17/328,354
- Filed: 2021-05-24
- Published: 2021-09-09
- Earliest claimed: 2019-05-07
- Inventors: Adam M. Rotunda
- Web page: https://patentgrep.com/patent/US20210275442A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 8/347: {Phenols}
- A61K 8/671: {Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal}
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 8/86: Polyethers
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 33/38: Silver; Compounds thereof
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61L 15/44: Medicaments
- A61L 26/0066: {Medicaments; Biocides}
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 2300/30: Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
- A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Cannabidiol (CBD) is one of the most abundant and physiologically active phytocannabinoids in Cannabis plants. The chemical has well-known mechanisms that have been the potential to treat and prevent numerous inflammatory, immunologic, anti-infectious, sun-damaged, age-related (wrinkling, drying, hair loss), and neurogenic-related (anti-pain, anti-itch) diseases as well as heal traumatized skin. The incorporation of CBD on or within topically applied formulations or within wound care dressings, biomaterials skin substitutes, or skin adhesives is a novel approach to alleviate, prevent and cure acute and chronic skin disease, and promote normal healing and recovery after injury.

## Claims

### Claim 1

An augmented topical medical system, the augmented topical medical system comprising:
a topical skin rejuvenation product configured to perform at least a first medical function ensuing from application of the topical product at a site of application; and
a drug release mechanism in physical association with the topical product, the drug release mechanism being configured to deliver cannabidiol at the site of application;
wherein the delivery of cannabidiol at the site of application is configured to augment the performance of the first medical function by the topical product.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The augmented topical medical system of claim 2, wherein the topical skin rejuvenation product comprises one or more of: a moisturizer, a hydration cream, a vitamin A derivative, a hyaluronic acid, glycerol, polyethylene glycol, dimethicone.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)
